These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 13679470)

  • 1. The value proposition of investigator-initiated clinical trials conducted by networks.
    joint ACTA/ACSQHC Working Group
    Med J Aust; 2021 Mar; 214(4):159-161.e1. PubMed ID: 33583043
    [No Abstract]   [Full Text] [Related]  

  • 2. Exploring non-retention in clinical trials: a meta-ethnographic synthesis of studies reporting participant reasons for drop out.
    Skea ZC; Newlands R; Gillies K
    BMJ Open; 2019 Jun; 9(6):e021959. PubMed ID: 31164359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What can we learn from trial decliners about improving recruitment? Qualitative study.
    Hughes-Morley A; Young B; Hempel RJ; Russell IT; Waheed W; Bower P
    Trials; 2016 Oct; 17(1):494. PubMed ID: 27733181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financial considerations in the conduct of multi-centre randomised controlled trials: evidence from a qualitative study.
    Snowdon C; Elbourne DR; Garcia J; Campbell MK; Entwistle VA; Francis D; Grant AM; Knight RC; McDonald AM; Roberts I
    Trials; 2006 Dec; 7():34. PubMed ID: 17184521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients.
    Soldini D; Zwahlen H; Gabutti L; Marzo A; Marone C
    Eur J Clin Pharmacol; 2005 Feb; 60(12):859-64. PubMed ID: 15657783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Money and morals: ending clinical trials for financial reasons.
    Eaton ML; Kwon BK; Scott CT
    Curr Top Behav Neurosci; 2015; 19():297-315. PubMed ID: 25062706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of finder's fees in clinical research.
    Maher EA
    CMAJ; 1994 Jan; 150(2):252-6. PubMed ID: 8287347
    [No Abstract]   [Full Text] [Related]  

  • 8. [Promoting research from the viewpoint of industry].
    Specker M
    Langenbecks Arch Chir Suppl Kongressbd; 1997; 114():347-51. PubMed ID: 9574152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research cooperation with industry from the viewpoint of surgery].
    Pichlmayr R
    Langenbecks Arch Chir Suppl Kongressbd; 1997; 114():352-7. PubMed ID: 9574153
    [No Abstract]   [Full Text] [Related]  

  • 10. Costs of research and patent considerations.
    Vickery BH
    J Androl; 1987; 8(1):S27-32. PubMed ID: 3549653
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug costs: research and development costs: the great illusion.
    Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stopping a medical research project for financial reasons.
    Drueke TB; Descamps-Latscha B; Locatelli F
    Nephrol Dial Transplant; 2003 Oct; 18(10):1982-3. PubMed ID: 13679470
    [No Abstract]   [Full Text] [Related]  

  • 13. [Expectations of the bearer of the cost of clinical studies and transformation to care by physicians under contract].
    Perleth M
    Dtsch Med Wochenschr; 2005 Jul; 130 Suppl 2():S72-6. PubMed ID: 15988672
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.